Cynapsus Therapeutics, Inc. (NASDAQ: CYNA)  is a specialty central nervous system pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand turning ON of debilitating OFF episodes associated with Parkinson’s disease (PD). The company’s lead product candidate, APL-130277, is a sublingual formulation of apomorphine hydrochloride, or apomorphine. Cynapsus has initiated its phase 3 clinical program for APL-130277, and intends to submit a new drug application in 2016. For more information, visit the company’s website at www.cynapsus.ca